BioAge Labs to Present at Upcoming Investor Conferences

Rhea-AI Summary

BioAge Labs (NASDAQ: BIOA), a clinical-stage biotechnology company focused on developing therapeutics for metabolic diseases through aging biology, has announced its participation in two major investor conferences in September 2025.

The company will present at Citi's 2025 Biopharma Back to School Conference in Boston (September 2-3) and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York (September 8-10). CEO Kristen Fortney and CFO Dov Goldstein will conduct fireside chats and one-on-one meetings at both events. Webcasts will be available live and archived for 30 days on the company's investor relations website.

EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:

• Citi’s 2025 Biopharma Back to School Conference (Boston, September 2–3, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Wednesday, September 3 at 3:15–3:55 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
  
  
• Morgan Stanley 23rd Annual Global Healthcare Conference (New York, September 8–10, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Wednesday, September 10 at 10:00–10:45 AM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here.

Replays of the webcasts will be available in the investor section of the company's website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity. BGE-102 has demonstrated significant weight loss in preclinical models both as monotherapy and in combination with GLP-1 receptor agonists. A Phase 1 SAD/MAD trial of BGE-102 is underway, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com

FAQ

When is BioAge Labs (BIOA) presenting at the Citi Biopharma Conference 2025?

BioAge Labs will present at the Citi Biopharma Conference on Wednesday, September 3, 2025, from 3:15 to 3:55 PM EDT.

When is BioAge Labs (BIOA) presenting at the Morgan Stanley Healthcare Conference 2025?

BioAge Labs will present at the Morgan Stanley Healthcare Conference on Wednesday, September 10, 2025, from 10:00 to 10:45 AM EDT.

Who will be presenting at the BioAge Labs (BIOA) investor conferences?

CEO and co-founder Kristen Fortney, PhD, along with CFO Dov Goldstein, MD, will be presenting at both conferences.

How can investors access BioAge Labs (BIOA) conference presentations?

Investors can access the live webcasts through registration links provided for each conference, and replays will be available for 30 days at https://ir.bioagelabs.com/.

What type of company is BioAge Labs (BIOA)?

BioAge Labs is a clinical-stage biotechnology company that develops therapeutic products for metabolic diseases by targeting the biology of human aging.